ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter

Key Takeaways

• FDA issued Warning Letter finding ImmunityBio’s promotional communications for Anktiva were “false or misleading”
• Securities fraud class action lawsuit filed against company for allegedly promoting unapproved drug uses
• Anktiva is only approved for narrow subset of bladder cancer patients, not as universal cancer cure as allegedly promoted

---

ImmunityBio (NASDAQ: IBRX) is facing a securities fraud class action lawsuit following an FDA Warning Letter that determined the company engaged in false and misleading promotional activities for its bladder cancer drug Anktiva.

The FDA’s Warning Letter, dated March 13, 2026, found that ImmunityBio’s promotional communications created “a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.” This represents a significant regulatory compliance failure for the biotechnology company.

Approved Indication vs. Alleged Promotion

Anktiva is approved by the FDA only for a highly specific patient population: those with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. This represents a narrow subset of bladder cancer patients who have not responded to standard BCG therapy.

The lawsuit alleges that ImmunityBio made material misrepresentations about the drug’s capabilities, potentially misleading investors and patients about its broader therapeutic potential beyond this limited approved indication.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for oncology - bladder cancer, with Anktiva most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Legal and Regulatory Implications

The securities fraud lawsuit, being pursued by law firm Levi & Korsinsky, seeks to represent investors who suffered losses due to the alleged promotional misconduct. Investors with significant losses may seek to lead the class action against the company.

Off-label promotion of prescription drugs is strictly regulated by the FDA. Companies can face serious penalties including:

• Civil monetary penalties
• Criminal charges in severe cases
• Consent decrees restricting promotional activities
• Enhanced FDA oversight of marketing materials

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Investor Concerns

The dual regulatory and legal challenges represent a significant setback for ImmunityBio’s commercial strategy. The company now faces:

• Potential substantial financial settlements
• Increased regulatory scrutiny of all promotional materials
• Possible restrictions on marketing activities
• Reputational damage affecting physician and investor confidence

For the broader oncology market, this case underscores the critical importance of compliance with FDA promotional guidelines, particularly for companies with limited approved indications seeking to build commercial momentum.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology - bladder cancer pricing, access, and launch sequencing.

What’s Next

The class action lawsuit will proceed through federal court, with the timeline for resolution potentially extending months or years. Meanwhile, ImmunityBio must respond to the FDA Warning Letter within 15 business days, outlining corrective actions to address the promotional violations.

The company’s ability to maintain its approved Anktiva indication remains intact, but any future promotional activities will likely face heightened regulatory scrutiny. Investors and patients should monitor upcoming company communications for evidence of compliance improvements and legal resolution progress.

---

Frequently Asked Questions

What does this mean for patients currently taking Anktiva?

Patients currently prescribed Anktiva for the approved bladder cancer indication can continue treatment as directed by their physicians. The FDA’s concerns relate to promotional communications, not the drug’s safety or efficacy for its approved use.

How serious are the allegations against ImmunityBio?

The allegations are significant, involving both FDA regulatory violations and securities fraud claims. The FDA determined promotional communications were false and misleading, which can result in substantial penalties and operational restrictions.

What happens to ImmunityBio’s stock and business operations?

The company faces potential financial penalties from both regulatory settlements and class action litigation. Operations will likely continue under increased FDA oversight, but promotional activities may be restricted pending resolution.

IntelligenceStrategic Takeaways▾

FDA issued Warning Letter finding ImmunityBio’s promotional communications for Anktiva were “false or misleading” Securities fraud class action lawsuit filed against company for allegedly promoting unapproved drug uses Anktiva is only approved for narrow subset of bladder cancer patients, not as universal cancer cure as allegedly promoted

Related profiles

• ANKTIVA

Related coverage

• Ecosystem Over Geography: Life Sciences Location Strategy in APAC